The global helicobacter pylori non-invasive testing market is projected to register at a moderate-paced CAGR of 4.4% over the forecast period. The helicobacter pylori non-invasive testing market is currently valued at USD 650.50 Million in 2023. By 2033, demand for helicobacter pylori non-invasive testing is expected to reach a high of USD 1000.57 Million.
This growth in the adoption of helicobacter pylori non-invasive testing is supported by the following:
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Immunoassays are biochemical tests that determine how much of an analyte is present. It doesn't matter what size the analyte is; it might be a huge protein, an antibody the body has created in response to an illness or a little molecule. The accuracy and reliability of immunoassays are unparalleled. They are very specific since antibodies and purified antigens are used as reagents. Diseases can be diagnosed more precisely using this assay since it measures antigen presence. It is a highly selective bioanalytical approach that uses an antibody or antigen as a biorecognition agent to quantify the presence or quantity of analytes ranging from tiny molecules to macromolecules in solution.
Due to the presence of several advanced technologies, such as the enzyme immunoassays, which are used for the detection of antibodies, the immunoassay segment currently holds a significant market share in the helicobacter pylori non-invasive testing market and is expected to show a similar trend over the forecast period. Key factors propelling the immunoassay market are the growing incidence of gastritis and infections caused by Helicobacter pylori, as well as technical developments.
For instance, in 2021, the worldwide prevalence of gastritis was estimated to be between 50.0% and 56.0%, according to a study titled "Diagnosis of Helicobacter pylori Infection and Recent Advances," with the prevalence of chronic atrophic gastritis falling within that range between 20% and 30%. Helicobacter pylori infection was shown to be proportional to gastritis prevalence, and cases of Helicobacter pylori-positive gastritis were found to account for more than 80.0% of all cases. Since such illnesses are typically detected by immunoassays, rising instances of Helicobacter pylori infection and gastritis are expected to drive the segment growth throughout the forecast period.
| Attributes | Details |
|---|---|
| Market Value (2023) | USD 650.50 Million |
| Market Value (2033) | USD 1000.57 Million |
| CAGR | 4.4% |
Increased Patient Requirement for POC Increases the Demand for H. pylori Tests Drives the Development of the Industry as a Whole
The National Institutes of Health (NIH) research states that IgG serology, the C-Urea Breath Test (UBT), and the monoclonal stool antigen test are all non-invasive, Point-of-care (POC) diagnostic options for primary care settings that can detect H. pylori. UBT is the only one of these that reliably verifies whether an infection is present or has been eradicated. According to the research published in Gut and Liver, UBT is an accurate, non-invasive option that is safe for use on both children and pregnant women.
In addition, H. pylori laboratory test results can now be obtained in a shorter amount of time owing to Point-of-care Testing (POCT), a tried-and-true method. Popularity, the number of people getting tested, and the variety of therapeutic uses for POCTs have all increased as leading companies keep releasing new models. In addition, Point-of-care Testing (POCT) is now widely used in all hospitals and is increasingly being adopted as the norm in other types of healthcare facilities. The global helicobacter pylori non-invasive testing market is expected to expand because of the aforementioned factors throughout the forecast period. This means that the increasing number of H. pylori sufferers is a key factor propelling the helicobacter pylori non-invasive testing market forward.
The industry's growth may be hampered by a lack of educated doctors to perform intrusive tests.
To accurately diagnose Helicobacter pylori infection and determine the best course of therapy, a surgeon or medical professional must perform an invasive procedure that often includes a biopsy and endoscopy. Market growth could be stymied, however, if countries with fewer healthcare resources and a corresponding shortage of trained professionals saw a decline in the number of people getting their diseases checked out. Unfortunately, many nations with low or middle income lack the hospital and medical training infrastructure necessary to produce highly qualified physicians. However, there are additional difficulties for doctors when treating Helicobacter pylori, as no first-line therapy is effective for everyone.
The helicobacter pylori non-invasive testing market is expected to expand at a modest rate worldwide. Although testing has become more common, diagnosis has been hindered by the fact that HIV infection often has no outward symptoms. This is a major factor in the market's slow expansion. It is also expected that h. pylori non-invasive testing is expected to decrease as attention is redirected to ending the current coronavirus pandemic.
Principal Consultant
From 2023 to 2033, the clinic market is expected to grow at a CAGR of over 6%, as more people choose clinics over hospitals because of their lower costs and higher quality of care. The reason for this is that people are more likely to seek help from clinics since they offer high-quality care and respond quickly to patient needs, resulting in effective treatment at an affordable price. The premium services provided by clinics as a result of efficient disease management tactics are also expected to fuel market growth.
Due to its non-invasive nature and its ability to offer speedy findings, the POC testing segment accounted for more than 35% of the business. This is due, in large part, to rising Research and Development spending and joint research activities amongst industry heavyweights that are fostering innovation and new product development.
The helicobacter pylori non-invasive testing market may be broken down into two distinct subsegments: invasive helicobacter pylori tests and non-invasive helicobacter pylori tests. Since quick urease tests are both effective and inexpensive, this market subsegment is expected to grow at a CAGR of 6.5% between 2023 and 2032. Patients who do not respond well to antibiotic medication, who have symptoms of severe gastrointestinal issues, and who require gastric endoscopy have a significant demand for invasive diagnostic methods.
Globally, North America accounts for the largest helicobacter pylori non-invasive testing market. The expansion of healthcare infrastructure in addition to the rising incidence of stomach cancer, duodenal ulcers, and gastric ulcers in North America are driving forces behind the helicobacter pylori non-invasive testing market's expansion.
The NIH found that 5 percent of USA youngsters under the age of 10 have H. pylori in their systems. In addition, 30% to 40% of Americans have H. pylori infection, according to research from the USA Department of Health and Human Services. Furthermore, socioeconomic variables such as poor income, less education, home crowding, and immigration all contribute to a higher prevalence of H. pylori infection in the USA's Hispanic and Black populations. In order to treat H. pylori, the FDA recommends either Proton Pump Inhibitors (PPI) and two antibiotics or bismuth subsalicylate, acid suppressors, and two antibiotics, as detailed in a paper available from the ClinMed International Library.
There is resistance to effectiveness with the currently available first-line medication regimens. Due to resistance in H. pylori to common antibiotics, the USA, for example, observed 75% eradication rates utilizing these regimens. The largest rates of resistance are shown with Clarithromycin and Metronidazole Fand characteristics related to resistance include race, age, location, and the presence or absence of ulcer disease.
The market for non-invasive testing for Helicobacter Pylori (H. pylori) in Asia and the Pacific is dominated by China. When it comes to healthcare and pharmaceuticals, China is a developing powerhouse in the Asia-Pacific region. Many international manufacturers of medical, pharmaceutical, and biotechnology products are based in China. High rates of H. pylori infection and gastric (stomach) cancer cases have spurred the development of diagnostic testing kits and technologies for H. pylori detection by pharmaceutical and biotechnology firms.
The Japanese medical industry is among the world's most advanced markets. Due to widespread infection with H. pylori and a penchant for consuming smoked and salted foods, Roswell Park Comprehensive Cancer Center reports that Japan has an alarmingly high incidence of stomach cancer. In Japan, 50,000 individuals each year are killed by stomach cancer, making it the third deadliest form of the disease. In addition, 98% of gastric cancer in Japan can be attributed to H. pylori, according to a study published in 2020 by Wiley Online Library.
Recent investigations have indicated that H. pylori infection is the primary cause of stomach cancer, while it is one of many factors. The expansion of the helicobacter pylori non-invasive testing market in Japan is anticipated to benefit from the aforementioned factors over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Companies like DiaSorin S.p.A., Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Alere, Thermo Fisher Scientific, Biomerica, Inc., Certest Biotec S.L., Sekisui Diagnostics, CorisBioconcept SPRL, and Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. are all major players in the global helicobacter pylori market. These leaders are anticipated to retain their positions of prominence during the prediction horizon.
Some recent developments in the helicobacter pylori non-invasive testing market include:
Meridian Bioscience, Inc. announced in March 2020 that its novel Curian and Curian HpSA assay had been approved by the Food and Drug Administration. They hope that their efforts to preserve their position as the industry leader in testing for gastrointestinal diseases would be aided by the introduction of this analyzer and its initial assay.
Thermo Fischer Scientific announced in December 2021 that it would be purchasing PPD, Inc. for USD17.4 billion. PPD is a top global provider of clinical research services to the biopharma & biotech industry.
The growth outlook for the Helicobacter Pylori Non-Invasive Testing market is predicted to advance at a CAGR of 4.4% from 2023 to 2033.
Europe region is anticipated to lead the Helicobacter Pylori Non-Invasive Testing market over the forecast period.
The valuation of the Helicobacter Pylori Non-Invasive Testing market stands at US$ 650.50 Million in 2023.
The Helicobacter Pylori Non-Invasive Testing market is likely to hold a valuation of US$ 1000.57 Million by 2033.
1. Executive Summary | Helicobacter Pylori Non-Invasive Testing Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Test Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2022 to 2032
5.3.1. Serology Test
5.3.2. Stool Antigen Test (SAT)
5.3.3. Urea Breath Test (UBT)
5.4. Y-o-Y Growth Trend Analysis By Test Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Test Type, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Test Method
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Test Method, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Method, 2022 to 2032
6.3.1. Laboratory-based Tests
6.3.2. Point-of-Care Tests
6.4. Y-o-Y Growth Trend Analysis By Test Method, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Test Method, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End-user
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2022 to 2032
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Diagnostic Laboratories
7.4. Y-o-Y Growth Trend Analysis By End-user, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By End-user, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East and Africa(MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Test Type
9.2.3. By Test Method
9.2.4. By End-user
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Test Type
9.3.3. By Test Method
9.3.4. By End-user
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Test Type
10.2.3. By Test Method
10.2.4. By End-user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Test Type
10.3.3. By Test Method
10.3.4. By End-user
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Test Type
11.2.3. By Test Method
11.2.4. By End-user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Test Type
11.3.3. By Test Method
11.3.4. By End-user
11.4. Key Takeaways
12. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Test Type
12.2.3. By Test Method
12.2.4. By End-user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Test Type
12.3.3. By Test Method
12.3.4. By End-user
12.4. Key Takeaways
13. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Test Type
13.2.3. By Test Method
13.2.4. By End-user
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Test Type
13.3.3. By Test Method
13.3.4. By End-user
13.4. Key Takeaways
14. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Test Type
14.2.3. By Test Method
14.2.4. By End-user
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Test Type
14.3.3. By Test Method
14.3.4. By End-user
14.4. Key Takeaways
15. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of Middle East and Africa(MEA)
15.2.2. By Test Type
15.2.3. By Test Method
15.2.4. By End-user
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Test Type
15.3.3. By Test Method
15.3.4. By End-user
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2021
16.1.2.1. By Test Type
16.1.2.2. By Test Method
16.1.2.3. By End-user
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2021
16.2.2.1. By Test Type
16.2.2.2. By Test Method
16.2.2.3. By End-user
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2021
16.3.2.1. By Test Type
16.3.2.2. By Test Method
16.3.2.3. By End-user
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2021
16.4.2.1. By Test Type
16.4.2.2. By Test Method
16.4.2.3. By End-user
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2021
16.5.2.1. By Test Type
16.5.2.2. By Test Method
16.5.2.3. By End-user
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2021
16.6.2.1. By Test Type
16.6.2.2. By Test Method
16.6.2.3. By End-user
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2021
16.7.2.1. By Test Type
16.7.2.2. By Test Method
16.7.2.3. By End-user
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2021
16.8.2.1. By Test Type
16.8.2.2. By Test Method
16.8.2.3. By End-user
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2021
16.9.2.1. By Test Type
16.9.2.2. By Test Method
16.9.2.3. By End-user
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2021
16.10.2.1. By Test Type
16.10.2.2. By Test Method
16.10.2.3. By End-user
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2021
16.11.2.1. By Test Type
16.11.2.2. By Test Method
16.11.2.3. By End-user
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2021
16.12.2.1. By Test Type
16.12.2.2. By Test Method
16.12.2.3. By End-user
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2021
16.13.2.1. By Test Type
16.13.2.2. By Test Method
16.13.2.3. By End-user
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2021
16.14.2.1. By Test Type
16.14.2.2. By Test Method
16.14.2.3. By End-user
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2021
16.15.2.1. By Test Type
16.15.2.2. By Test Method
16.15.2.3. By End-user
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2021
16.16.2.1. By Test Type
16.16.2.2. By Test Method
16.16.2.3. By End-user
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2021
16.17.2.1. By Test Type
16.17.2.2. By Test Method
16.17.2.3. By End-user
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2021
16.18.2.1. By Test Type
16.18.2.2. By Test Method
16.18.2.3. By End-user
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2021
16.19.2.1. By Test Type
16.19.2.2. By Test Method
16.19.2.3. By End-user
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2021
16.20.2.1. By Test Type
16.20.2.2. By Test Method
16.20.2.3. By End-user
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2021
16.21.2.1. By Test Type
16.21.2.2. By Test Method
16.21.2.3. By End-user
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Test Type
17.3.3. By Test Method
17.3.4. By End-user
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. DiaSorin S.p.A.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Meridian Bioscience, Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Exalenz Bioscience Ltd.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Alere
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Thermo Fisher Scientific
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Biomerica, Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Certest Biotec S.L.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Sekisui Diagnostics
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. CorisBioconcept SPRL
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Helicobacter Pylori Non-Invasive Testing Market
